FDA warns about stevia in iced tea mix
This article was originally published in The Tan Sheet
Executive Summary
Hain Celestial Group's use of stevia in its Celestial Seasonings Zingers to Go Tangerine Orange Wave Herb Tea constitutes an adulterated food product violating regulations under the Food, Drug and Cosmetic Act, the FDA says in Aug. 17 warning letter. The product is a food "subject to regulation as a conventional food and not a dietary supplement," although the Zinger product label states, "Herbal Supplement," and also includes a supplement facts panel for nutrition labeling, according to FDA. Stevia has not been generally recognized as safe as a food additive, therefore cannot be added to conventional food products, such as powder drink mixes, the agency states. Safety concerns surrounding the natural sweetener include it effects on blood sugar as well as impacts on reproductive, cardiovascular and renal systems, FDA states in the letter. The agency began allowing the import of stevia in 1995 as a supplement ingredient, but considers it an unsafe food additive ("The Tan Sheet" Sept. 25, 1995, In Brief)...
You may also be interested in...
In Brief: Stevia import alert
Stevia import alert: FDA revises three-year import alert on the herbal ingredient stevia on Sept. 18. FDA will allow importation of the ingredient if it is labeled as a dietary supplement or if it is to be used solely in the production of a dietary supplement product. It will be considered an unsafe food additive if used in a dietary supplement for a "technical effect," such as sweetening and flavoring and is labeled as such, the agency said. FDA says data are currently inadequate to approve stevia as a food additive or affirm the ingredient as GRAS. The American Herbal Products Association petitioned the agency to affirm the GRAS status of stevia, which is said to be 250-300 times sweeter than sugar and without calories...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.